- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pathophysiology of Pulmonary Arterial Hypertension
Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major therapeutic targets including nitric oxide, endothelin, prostacyclin, and activin signaling inhibition.
EP: 1.Pathophysiology of Pulmonary Arterial Hypertension
EP: 2.Differential Diagnosis of Pulmonary Arterial Hypertension
EP: 3.Importance of Early Detection and Monitoring for Disease Progression
EP: 4.Risk Stratification and the Importance of Patient-Centered Care
EP: 5.Strengths and Limitations of Current Therapeutic Options
EP: 6.Overview of Different Therapies for Patients with Pulmonary Arterial Hypertension
EP: 7.Sotatercept for Patients with Pulmonary Arterial Hypertension
EP: 8. The Role of the Prostacyclin Pathway
EP: 9.Important Clinical Considerations for Pulmonary Arterial Hypertension
EP: 10.Economic Impact of Pulmonary Arterial Hypertension
EP: 11.Barriers to Care for Patients with Pulmonary Arterial Hypertension
EP: 12.Utilizing Health Economic Outcomes in Clinical Practice
EP: 13.Outlining the Need for Equitable Access to Care
EP: 14.Final Panelist Thoughts on the Management of Pulmonary Arterial Hypertension
Pathophysiology and Treatment Pathways
Pulmonary arterial hypertension (PAH) represents a complex disease with multifaceted pathophysiology involving over 20 identified genetic mutations that can contribute to disease development. The condition affects pulmonary vasculature and capillaries, causing narrowing that increases workload on the right ventricle and heart. Understanding these underlying mechanisms is crucial for effective disease management and treatment selection.
From a therapeutic perspective, PAH management has evolved to target four distinct treatment pathways, expanding from the traditional three-pathway approach. These pathways focus on nitric oxide signaling, endothelin receptor antagonism, prostacyclin pathway modulation, and the newer activin signaling inhibition. Each pathway offers unique mechanisms of action that can be leveraged individually or in combination to address the disease's complexity.
The multi-pathway approach to PAH treatment reflects the disease's heterogeneous nature and the need for personalized therapeutic strategies. By targeting different biological pathways simultaneously, clinicians can maximize treatment efficacy while addressing the various contributing factors to pulmonary vascular dysfunction. This comprehensive understanding of pathophysiology guides modern treatment algorithms and supports the development of innovative therapeutic approaches.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
